Analgesic use of N-L-.alpha.-aspartyl-L-phenylalanine 1-methyl e

Details Analgesic use of N-L-.alpha.-aspartyl-L-phenylalanine 1-methyl e Analgesic use of N-L-.alpha.-aspartyl-L-phenylalanine 1-methyl e

1997-12-22

1999-12-07

Henley, III, Raymond

Drug, bio-affecting and body treating compositions

Designated organic active ingredient containing

Ester doai

A61K 3124

Patent

active

059984732

DESCRIPTION:

BRIEF SUMMARY
TECHNICAL FIELD

The present invention relates to pain relieving composition and a method for use.


BACKGROUND OF THE INVENTION

Pain is the most common symptom for which patients seek medical assistance. In the case of incurable diseases, treatment for pain may last for extended periods of time. Pain is both a physical and an emotional experience which differs greatly from one individual to another. Although subjective, most pain is associated with tissue damage and has a physiological basis.
Pain can be either acute or chronic. Acute pain is generally caused by sudden injury, tissue damage, or infection for which the cause is easily found. Chronic pain, however, is the pain of pathological conditions and often difficult to isolate and treat. Chronic pain is routinely defined as pain of over six months duration.
For patients suffering from chronic pain, the autonomic nervous system adapts to the pain and evidences of autonomic hyperactivity such as tachycardia, hypertension, diaphoresis, mydriasis, and pallor disappear, leaving the physician to rely on the patient's subjective complaints in assessing chronic pain.
In the management of chronic pain, some types of pain permit treatment of the underlying disorder, i.e., radiation treatment for pain caused by bone cancer. In some cases, a particular treatment is given for a specific type of pain, i.e., treatment of trigeminal neuralgia or glossopharyngeal neuralgia with carbamazepine, reflex sympathetic dystrophies with local anesthetic, postherpetic neuralgia with direct stimulation.
In many patients, however, the pain is chronic and the physician can neither treat the underlying disturbance nor prescribe a specific therapy for that type of pain. For example, osteoarthritis is a joint disease characterized by degeneration and loss of articular cartilage and by osteophyte formation, or bony outgrowth of subchondral bone. The disease is slowly progressive, leading to chronic pain and stiffness and gradually to increasing dysfunction of the affected joint. The incidence of the disease increases with age and affects three times as many women as men.
Chronic joint pain, swelling, creaking, and stiffness are the most prominent symptoms of osteoarthritis. The disease commonly affects the distal interphalangeal joints of the hands, resulting in bone enlargements often accompanied by inflammation and pain. Weight bearing joints such as the neck, lower back, knees and hips are often affected by this type of arthritis.
Another major symptom of osteoarthritis is loss of articulation of the joint. Weakness and shrinkage of surrounding muscles may occur if pain prevents the joint from being used regularly. As movement of an affected joint becomes severely limited, the sufferer experiences loss of functionality of the joint. In the case of osteoarthritis of the hip or knees, ambulation becomes impaired.
Although osteoarthritis is the most common of the rheumatic diseases, its pathogenesis is not well understood, and currently there is no treatment that will retard or reverse pathological processes in the disease. The only treatment available to osteoarthritis sufferers has involved symptomatic treatment through analgesics for pain and nonsteroidal anti-inflammatory agents for reduction of joint inflammation. An injection of a corticosteroid may also be administered to a painful joint.
Chronic pain is also associated with multiple sclerosis (MS), also known as disseminated or insular sclerosis, a disease of the central nervous system (CNS) characterized by widespread patches of demyelination in the brain and spinal cord. The disease occurs worldwide in about 10-60 persons per 100,000 with the age at onset occurring at about 20-40 years, and appears to affect females more often than males. While MS is generally chronic and relapsing, fulminating attacks occur, and as many as 30% of the patients progress steadily from the onset.
Although multiple sclerosis is the most common demyelinating disease, its cause is unknown, and there is no treatment to retard or reverse the patho

REFERENCES:
patent: 3492131 (1970-01-01), Schlatter
patent: 4689218 (1987-08-01), Gazzaniga et al.
patent: 5053393 (1991-10-01), Tjoeng
patent: 5053396 (1991-10-01), Blass
patent: 5496856 (1996-03-01), Creppy
patent: 5654334 (1997-08-01), Edmundson et al.
Douglas, W.W., "Polypeptides-angiotensin, plasma kinins, and other vasoactive agents; prostaglandins," The Pharmacological Basis of Therapeutics, 5th ed., L. S. Goodman and A. Gilman (eds.), MacMillan Publishing Co., Inc., New York, p. 647 (1975).
Guiso, et al., "Effect of tyrosine on the potentiation by aspartame and phenylalanine of metrazol-induced convulsions in rats," Fd. Chem Toxic 29:855-857 (1991).
Insel, Paul, "Analgesic-antipyretic and antiinflammatory agents and drugs employed in the treatment of gout," The Pharmacological Basis of Therapeutics, 9th ed., J. G. Hardman and L.E. Limbird (eds.), McGraw-Hill Companies, Inc., New York, pp. 620-622 (1996).
Leon, et al., "Safety of long-term large doses of aspartame," Arch Int Med 149:2318-2324 (1989).
Picot, et al., "The x-ray crystal structure of the membrane protein prostalandin H.sub.2 synthase-1," Nature 367:243-249 (1991).

Affiliated with

Also associated with

Rating

Analgesic use of N-L-.alpha.-aspartyl-L-phenylalanine 1-methyl e does not yet have a rating. At this time, there are no reviews or comments for this patent.

If you have personal experience with Analgesic use of N-L-.alpha.-aspartyl-L-phenylalanine 1-methyl e, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Analgesic use of N-L-.alpha.-aspartyl-L-phenylalanine 1-methyl e will most certainly appreciate the feedback.

Rate now

Comments { 0 }

Profile ID: LFUS-PAI-O-824552